UCB obtains extra rights for fibromyalgia syndrome drug

UCB, the Belgian pharmaceutical company, has revealed it has expanded its licensing agreement with Jazz Pharmaceuticals for Xyrem, a treatment for fibromyalgia syndrome.

Xyrem, which has been launched in the UK as a therapy for cataplexy in patients with narcolepsy, is currently undergoing a phase III clinical development programme to demonstrate its effectiveness in treating fibromyalgia syndrome – a disorder characterised by widespread aches, pains, stiffness, fatigue and sleep disturbance.

The drug has already been licensed to UCB in 27 countries, but the new expanded agreement with Jazz has seen that double to 54. UCB has also made an upfront payment to Jazz, which also stands to receive milestone and royalty payments, while continuing to market Xyrem in the US.

William Robinson, UCB’s executive vice president of global operations, said the company was “encouraged” by the start of phase III trials to evaluate Xyrem for fibromyalgia.

“Acquiring the rights to in-licence Xyrem for fibromyalgia syndrome demonstrates the ongoing commitment of UCB to satisfying unmet medical needs,” he stated.

Mr Robinson concluded by saying that he looked forward to launching the drug in “many more countries”.

According to the Fibromyalgia Association UK, the condition is as common as rheumatoid arthritis and “can be even more painful”.

The disorder is not fully understood and is characterised by a collection of symptoms rather than a specific disease process, the charity asserts.